Comparison of diphtheria-tetanus-two component acellular pertussis vaccines in United States and Japanese infants at 2, 4, and 6 months of age

Pediatrics

Volumn 97, Issue 2, 1996, Pages 236-242

  Rothstein, Edward P ^a,b,f   Kamiya, Hitoshi ^c   Nii, Ritsue ^c   Matsuda, Tadashi ^d   Bernstein, Henry H ^a,b   Long, Sarah S ^a   Hosbach, Philip H ^e   Meschievitz, Carlton K ^e  

^a ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^b Pennridge Pediatric Associates   (United States)

^c MIE NATIONAL HOSPITAL   (Japan)

^d Yonaha General Hospital   (Japan)

^e Connaught Laboratories ^*  (United States)

^f NONE   (United States)

Author keywords

acellular pertussis vaccine; filamentous hemagglutinin; immunogenicity; intramuscular immunization; pertussis toxoid; reactogenicity; subcutaneous immunization; whole cell pertussis vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; DIPHTHERIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERYTHEMA; FATIGUE; HUMAN; IMMUNIZATION; INFANT; INJECTION SITE; INTRAMUSCULAR DRUG ADMINISTRATION; JAPAN; MAJOR CLINICAL STUDY; PERTUSSIS; PRIORITY JOURNAL; SKIN MANIFESTATION; SUBCUTANEOUS DRUG ADMINISTRATION; TETANUS; UNITED STATES;

DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DOUBLE-BLIND METHOD; HUMANS; INFANT; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; JAPAN; UNITED STATES;

EID: 0030045406     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Cherry JD, Brunell PA, Golden GS, Karzon DT. Report of the Task Force on Pertussis and Pertussis Immunization-1988 Pediatrics. 1988; 81(suppl):939-984
2. Onorato IM, Wassilak SG, Meade B. Efficacy of whole-cell pertussis vaccine in preschool children in the United States JAMA 1992;267 2745-2749
3. Manclark CR, Cowell JL Pertussis. In: Germanier R, ed. Bacterial Vaccines New York Academic Press, 1984;69-106
4. Sato Y, Kimura M, Fukuma H. Development of a pertussis component vaccine in Japan. Lancet. 1984,1:122-126
5. Blennow M, Granström M, Jäätmaa E, Olin P Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial. Pediatrics. 1988;82:293-299
6. Edwards KM, Bradley RB, Decker MD, et al. Evaluation of a new highly purified pertussis vaccine in infants and children. J Infect Dis. 1989;160: 832-837
7. Pichichero ME, Francis AB, Blatter MM, et al. Acellular pertussis vaccination of 2-month-old infants in the United States. Pediatrics. 1992;89: 882-887
8. Feldman S, Perry S, Andrew M, et al. Comparison of acellular (B type) and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines as the first booster immunization in 15- to 24-month-old children J Pediatr. 1992;121 857-861
9. Bernstein HH, Rothstein EP, Pichichero ME, et al. Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children. Am J Dis Child. 1992;146:556-559
10. Kimura M, Kuno-Sakai H. Developments in pertussis immunization in Japan. Lancet. 1990,336:30-32
11. Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular-pertussis vaccines in Sweden-protective efficacy and adverse events. Lancet. 1988;1:955-960
12. Centers for Disease Control. Pertussis vaccination: acellular pertussis vaccine for the fourth and fifth doses of the DTP series. Update to the supplementary ACIP statement. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1992;41(no. RR-15):1-5
13. Manclark CR, Meade BD, Burstyn DG. Serological response to Bordetella pertussis. In: Rose NR, Freidman H, Fahey JL, eds Manual of Clinical Laboratory Immunology. 3rd ed. Washington, DC: American Society for Microbiology, 1986:338-394
14. Gillenius P, Jaatmaa E. Askelof P, Granstrom M, Tiru M. The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells J Biol Standard. 1985;13:61-66
15. Miyamura K, Nishi S, Ito A, Murato R, Kono R. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells. I. Studies on factors affecting the toxin and antitoxin titration J Biol Standard. 1974, 2 189-201
16. Committee on Infectious Diseases, American Academy of Pediatrics. Report of the Committee on Infectious Diseases 23rd ed. Elk Grove Village, IL. American Academy of Pediatrics, 1994 20
17. Immunization Practices Advisory Committee. Recommendations of the Immunization Practices Advisory Committee (ACIP): general recommendations on immunization. MMWR 1989;38:205-227
18. Watson B, Cawein A, McKee BL, Hackell JG. Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus as the Japanese commercial Takeda vaccine, compared with the Takeda acellular pertussis component combined with Lederle's diphtheria and tetanus toxoids in two-, four- and six-month-old infants Pediatr Infect Dis J. 1992,11.930-935
19. Kamiya H, Nii R, Matsuda T, Yasuda N, Christenson PD, Cherry JD. Immunogenicity and reactogenicity of Takeda acellular pertussiscomponent diphtheria-tetanus pertussis vaccine in 2- and 3-month old children in Japan. Am J Dis Child. 1992;146:1141-1147
20. Booy R, Aitkin SJM, Taylor S, et al. Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age. Lancet. 1992;339:507-510
21. Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human serum. J Biol Standard. 1983;11:137-144
22. Ohkuni H, Yabiku M, Togawa M, et al. Calculation of efficacy of acellular pertussis vaccine from the number of pertussis patients and vaccinees in three areas. Dev Biol Stand. 1991;73:43-49
23. Storsaeter J, Blackwelder WC, Hallander HO. Pertussis antibodies and vaccine efficacy after household exposure. Am J Dis Child. 1992;146: 167-172
24. Storsaeter J, Olin P. Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance. Vaccine. 1992;10:142-144
25. Aoyama T, Murase Y, Kato M, Iwai H, Iwata T. Efficacy and immunogenicity of acellular pertussis vaccine by manufacturer and patient age. Am J Dis Child. 1989;143:655-659
26. Halperin SA, Bortolussi R, MacLean D, Chisholm N. Persistence of pertussis in an immunized population: results of the Nova Scotia Enhanced Pertussis Surveillance Program. J Pediatr. 1989;115: 686-693
27. Fine PEM, Clarkson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis. 1987;9:866-883